EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction

Fengling Wang iD, Wenling Ye, Yongxing He, Haiyang Zhong, Yongchang Zhu, Jianting Han, Xiaoqing Gong, Yanan Tian, Yuwei Wang iD, Shuang Wang, Shaoping Ji, Huanxiang Liu iD und 1 weitere

International Journal of Molecular Sciences · 16.02.2023 · 24 (4) · 3971

DOI: 10.3390/ijms24043971 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 16.02.2023. Verfasst von Fengling Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou 730000, China. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Key Research & Development and Promotion Project of Henan Province, Science and Technology Development in Kaifeng City.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeting of the PD-1/PD-L1 immunologic checkpoint is believed to have provided a real breakthrough in the field of cancer therapy in recent years. Due to the intrinsic limitations of antibodies, the discovery of small-molecule inhibitors blocking PD-1/PD-L1 interaction has gradually opened valuable new avenues in the past decades. In an effort to discover new PD-L1 small molecular inhibitors, we carried out a structure-based virtual screening strategy to rapidly identify the candidate compounds. Ultimately, CBPA was identified as a PD-L1 inhibitor with a KD value at the micromolar level. It exhibited effective PD-1/PD-L1 blocking activity and T-cell-reinvigoration potency in cell-based assays. CBPA could dose-dependently elevate secretion levels of IFN-γ and TNF-α in primary CD4+ T cells in vitro. Notably, CBPA exhibited significant in vivo antitumor efficacy in two different mouse tumor models (a MC38 colon adenocarcinoma model and a melanoma B16F10 tumor model) without the induction of observable liver or renal toxicity. Moreover, analyses of the CBPA-treated mice further showed remarkably increased levels of tumor-infiltrating CD4+ and CD8+ T cells and cytokine secretion in the tumor microenvironment. A molecular docking study suggested that CBPA embedded relatively well into the hydrophobic cleft formed by dimeric PD-L1, occluding the PD-1 interaction surface of PD-L1. This study suggests that CBPA could work as a hit compound for the further design of potent inhibitors targeting the PD-1/PD-L1 pathway in cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Programmed Cell Death 1 ReceptorImmune Checkpoint InhibitorsAnimalsMiceAdenocarcinomaB7-H1 AntigenCD8-Positive T-LymphocytesColonic NeoplasmsMolecular Docking SimulationTumor Microenvironment

Stichwörter der Autor:innen

CBPAPD-1PD-L1cancer immunotherapysmall-molecule inhibitor

Substanzen

B7-H1 AntigenProgrammed Cell Death 1 ReceptorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou 730000, China.
  • Henan International Joint Laboratory for Nuclear Protein Regulation, Cell Signal Transduction Laboratory, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China.
  • Ministry of Education Key Laboratory of Cell Activities and Stress Adaptations, School of Life Sciences, Lanzhou University, Lanzhou 730000, China.
  • Faculty of Applied Science, Macao Polytechnic University, Macao 999078, China.
  • College of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang 712046, China.
  • State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau 999078, China.

ORCID-Profile: Fengling Wang, Yuwei Wang, Huanxiang Liu

Förderung

  • National Natural Science Foundation of China
  • Key Research & Development and Promotion Project of Henan Province
  • Science and Technology Development in Kaifeng City

Zitieren

APA

Wang, F., Ye, W., He, Y., Zhong, H., Zhu, Y., Han, J., Gong, X., Tian, Y., Wang, Y., Wang, S., Ji, S., Liu, H., & Yao, X. (2023). Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction. International Journal of Molecular Sciences, 24(4), 3971. https://doi.org/10.3390/ijms24043971

Vancouver

Wang F, Ye W, He Y, Zhong H, Zhu Y, Han J, et al. Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction. International Journal of Molecular Sciences. 2023;24(4):3971. doi:10.3390/ijms24043971

BibTeX
@article{Wang2023,
  author = {Wang, Fengling and Ye, Wenling and He, Yongxing and Zhong, Haiyang and Zhu, Yongchang and Han, Jianting and Gong, Xiaoqing and Tian, Yanan and Wang, Yuwei and Wang, Shuang and Ji, Shaoping and Liu, Huanxiang and Yao, Xiaojun},
  title = {Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {4},
  pages = {3971},
  doi = {10.3390/ijms24043971}
}
Kostenlos starten →